OpenScholar

Search results

302 results found

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Publication: Journal Article

Slabicki, M., Z. Kozicka, G. Petzold, Y. D. Li, M. Manojkumar, R. D. Bunker, K. A. Donovan, et al. 2020. “The CDK Inhibitor CR8 Acts As a Molecular Glue Degrader That Depletes Cyclin K”. Nature 585: 293-97.

Alissa Campbell

Person: 415 Main St.

Graduate student

Eriene Sidhom

Person: 415 Main St.

Graduate student

Jamie L Marshall

Person: 75 Ames St.

Senior Scientist

Jillian Shaw

Person: 75 Ames St.

Management

Josh Ketterman

Person:

Alfred L. George, MD

Person: Chair, Department of Pharmacology, Director, Center for Pharmacogenomics, Northwestern University

Shaun Purcell, Ph.D.

Person: Senior Associate, Broad Institute

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling

Page

https://depmap.org/repurposing/

Rishi Puram

Person: Postdoctoral Fellow

I am a postdoctoral fellow in the Golub lab using functional genomics and chemical screening approaches to define mechanism of action of epigenetic therapy in hematologic malignancies.